Dr. Michael Waters

Emergency Medicine
Office
754 Medical Center Ct Ste 202, 
Chula Vista, CA 
Referral may be required
Office
754 Medical Center Ct Ste 202, 
Chula Vista, CA 

Overview

Michael Waters is an Emergency Medicine provider practicing medicine in Chula Vista, California.

His clinical expertise encompasses Traumatic Brain Injury.

He is actively involved in clinical research, participating in 10 clinical trials.

Specialties

Emergency Medicine

Licenses

Emergency Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Office
754 Medical Center Ct Ste 202, Chula Vista, CA 91911

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19
Enrollment Status: Terminated
Publish Date: July 03, 2023
Intervention Type: Drug, Other
Study Drug: BGE-175
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).
Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Drug
Study Drug: VERU-111
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
Enrollment Status: Withdrawn
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials
Similar Doctors
Expertise in
5
conditions
Dr. Mary Gessner
Emergency Medicine
Expertise in
5
conditions
Dr. Mary Gessner
Emergency Medicine
Referral may be required

Office

1832 Alpine Blvd Ste B, 
Alpine, CA 
 (22.4 miles away)
619-326-4445
Languages Spoken:
English
See accepted insurances

Mary Gessner is an Emergency Medicine provider practicing medicine in Alpine, California. Dr. Gessner is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Opioid Induced Constipation, End-Stage Renal Disease (ESRD), Vitamin D Deficiency, Endoscopy, and Gastrostomy.

Expertise in
1
conditions
Dr. Benjamin Boni
Emergency Medicine
Expertise in
1
conditions
Dr. Benjamin Boni
Emergency Medicine
Referral may be required

Naval Hospital Camp Pendleton

200 Mercy Cir, 
Camp Pendleton, CA 
 (46.7 miles away)
760-725-4357
Languages Spoken:
English
See accepted insurances

Benjamin Boni is an Emergency Medicine provider practicing medicine in Camp Pendleton, California. Dr. Boni is highly rated in 1 condition, according to our data. His clinical expertise encompasses Schizoaffective Disorder.

Expertise in
1
conditions
Dr. Douglas Ballesteros
Emergency Medicine
Expertise in
1
conditions
Dr. Douglas Ballesteros
Emergency Medicine
Referral may be required

Scripps Mercy Hospital Chula Vista

435 H St, 
Chula Vista, CA 
 (3.7 miles away)
619-691-7290
Languages Spoken:
English
See accepted insurances

Douglas Ballesteros is an Emergency Medicine provider practicing medicine in Chula Vista, California. Dr. Ballesteros is highly rated in 1 condition, according to our data. His clinical expertise encompasses Schizoaffective Disorder, Traumatic Brain Injury, Inappropriate Sinus Tachycardia (IST), and Gallbladder Disease.

Frequently Asked Questions about Dr. Michael Waters

How do I make an appointment with Dr. Michael Waters?

You can book an appointment with Dr. Michael Waters by calling their office at 619-955-5246. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Waters a top-rated expert for Traumatic Brain Injury?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Waters is classified as an Experienced expert for Traumatic Brain Injury, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Waters specialize in?

While Dr. Michael Waters is a Emergency Medicine, they have specific expertise in Traumatic Brain Injury. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Emergency Medicine.

Does Dr. Michael Waters accept my insurance?

Dr. Michael Waters accepts most major insurance plans, including Medicaid and Wellcare. We recommend calling the office directly at 619-955-5246 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Waters's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile